Do you have mild-to-moderate hidradenitis suppurativa?

If you have mild to moderate hidradenitis suppurativa (HS) and you live in Australia, then you may be eligible to participate in a new clinical trial looking at the safety, tolerability and efficacy of a potential new topical medication.  The trial is 14 weeks long.  It consists of a 4-week run-in period , an 8 week treatment period, and a 2 week non-treatment follow up.  It is being conducted at multiple clinical sties across Australia.

Details of the clinical trial can be found here.

Please tell us about yourself and we will let you know if you may be eligible to participate.

State / Territory
Have you been diagnosed with or had signs of HS in the last 3 months?
Thanks for submitting your details.  If you are eligible for the study, a member of the clinical team will contact you.

Disclaimer - Choosing to participate in a study is an important personal decision. Talk with your doctor. family members or friends when considering to join a study.  AT193 has not been demonstrated to be safe or effective for any indication and is not available for sale in Australia or any other country. 

Your personal information is being requested to allow an initial assessment to be made about your potential eligibility for participation in a clinical trial.  By submitting the requested information, you are consenting for your personal and health information to be viewed by representatives from Azora Therapeutics and its affiliates, and disclosed to a relevant trial site for further assessment.  Your data will be stored on our servers until completion of the study.  It will not be used for any purposes other than the purpose stated above. Potential participants should contact us if they wish to have their information updated or removed from theses systems prior to the completion of the study.